Plain-English translation of NCT05719558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called in adults with advanced cancers that have spread or cannot be removed by surgery. The medication works by attaching to a specific protein on cancer cells, which signals your body's immune system to attack the tumor. Researchers are studying whether this treatment is safe, what the right dose should be, and whether it can slow down cancer growth—either on its own or combined with existing cancer drugs.
Many people with advanced solid tumors have limited treatment options, especially if they've already tried standard chemotherapy or immunotherapy. This medication targets a protein that appears on many types of cancer, offering a potentially new way to help the immune system recognize and fight cancer cells.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you may receive the new medication alone or in combination with standard chemotherapy or immunotherapy drugs. The study starts by testing lower doses and gradually increases them to find the safest and most effective dose. You will have regular visits to the clinic for treatment administration, blood tests, imaging scans, and biopsies to monitor how the medication works and how your body tolerates it. The study involves multiple phases, with some participants helping researchers find the right dose and others receiving the selected dose to see if the treatment shows promise against specific cancer types.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.